Cargando…
Post-mRNA vaccine flares in autoimmune inflammatory rheumatic diseases: Results from the COronavirus National Vaccine registry for ImmuNe diseases SINGapore (CONVIN-SING)
BACKGROUND: Studies of flares of autoimmune inflammatory rheumatic diseases (AIIRD) after COVID-19 mRNA vaccination are limited by small sample size, short follow up or at risk of selection bias. METHODS: A national retrospective cohort study of consecutive AIIRD patients ≥12 years old, across 8 hos...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705203/ https://www.ncbi.nlm.nih.gov/pubmed/36473406 http://dx.doi.org/10.1016/j.jaut.2022.102959 |
_version_ | 1784840226823208960 |
---|---|
author | Ma, Margaret Santosa, Amelia Fong, Warren Chew, Li-Ching Low, Andrea HL Law, Annie Poh, Yih Jia Yeo, Siaw Ing Leung, Ying Ying Ng, Victoria WW Koh, Joshua ZE Tay, Sen Hee Mak, Anselm Teng, Gim Gee Xu, Chuanhui Tang, Johnston GX Kong, Kok Ooi Angkodjojo, Stanley Goh, Wei-Rui Chuah, Tyng Yu Roslan, Nur Emillia Arkachaisri, Thaschawee Teh, Kai Liang Sriranganathan, Melonie Tan, Teck Choon Phang, Kee Fong Yap, Qai Ven Chan, Yiong Huak Cheung, Peter PM Lahiri, Manjari |
author_facet | Ma, Margaret Santosa, Amelia Fong, Warren Chew, Li-Ching Low, Andrea HL Law, Annie Poh, Yih Jia Yeo, Siaw Ing Leung, Ying Ying Ng, Victoria WW Koh, Joshua ZE Tay, Sen Hee Mak, Anselm Teng, Gim Gee Xu, Chuanhui Tang, Johnston GX Kong, Kok Ooi Angkodjojo, Stanley Goh, Wei-Rui Chuah, Tyng Yu Roslan, Nur Emillia Arkachaisri, Thaschawee Teh, Kai Liang Sriranganathan, Melonie Tan, Teck Choon Phang, Kee Fong Yap, Qai Ven Chan, Yiong Huak Cheung, Peter PM Lahiri, Manjari |
author_sort | Ma, Margaret |
collection | PubMed |
description | BACKGROUND: Studies of flares of autoimmune inflammatory rheumatic diseases (AIIRD) after COVID-19 mRNA vaccination are limited by small sample size, short follow up or at risk of selection bias. METHODS: A national retrospective cohort study of consecutive AIIRD patients ≥12 years old, across 8 hospitals who received at least one dose of a COVID-19 mRNA vaccine. Patients were included from the date of 1st vaccine dose and censored at the time of flare or on the date of the clinic visit at least 3 months from cohort entry, whichever came first. Predictors of flare were determined by Cox proportional hazards analysis. FINDINGS: 4627 patients (73% Chinese, 71% female) of median (IQR) age 61 (48, 70) years were included; 42% Rheumatoid arthritis, 14% Systemic lupus erythematosus and 11% Psoriatic arthritis. 47% were in remission, 41% low disease activity, 10% moderate disease activity and 1% in high disease activity. 18% patients flared, of which 11.7% were within the 3-month period of interest. 11.8% patients improved. Median (IQR) time-to-flare was 60 (30, 114) days. 25% flares were self-limiting, 61% mild-moderate and 14% severe. Older patients (53–65 years and >66 years) had a lower risk of flare [HR 0.6 (95% CI 0.5–0.8) and 0.7 (0.6–0.8) respectively]. Patients with inflammatory arthritis and with active disease had a higher risk of flare [HR 1.5 (1.2–2.0) and 1.4 (1.2–1.6), respectively]. Treatment with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), immunosuppression and prednisolone was also associated with an increased risk of flare [HR 1.5 (1.1–2), 1.2 (1.1–1.4) and 1.5 (1.2–1.8) for prednisolone ≤7.5 mg respectively]. INTERPRETATION: There was a moderately high rate of AIIRD flares after mRNA vaccination but also improvement in several patients. Severe flares and hospitalisation were rare. Thus, vaccination remains safe and highly recommended. |
format | Online Article Text |
id | pubmed-9705203 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | The Authors. Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97052032022-11-29 Post-mRNA vaccine flares in autoimmune inflammatory rheumatic diseases: Results from the COronavirus National Vaccine registry for ImmuNe diseases SINGapore (CONVIN-SING) Ma, Margaret Santosa, Amelia Fong, Warren Chew, Li-Ching Low, Andrea HL Law, Annie Poh, Yih Jia Yeo, Siaw Ing Leung, Ying Ying Ng, Victoria WW Koh, Joshua ZE Tay, Sen Hee Mak, Anselm Teng, Gim Gee Xu, Chuanhui Tang, Johnston GX Kong, Kok Ooi Angkodjojo, Stanley Goh, Wei-Rui Chuah, Tyng Yu Roslan, Nur Emillia Arkachaisri, Thaschawee Teh, Kai Liang Sriranganathan, Melonie Tan, Teck Choon Phang, Kee Fong Yap, Qai Ven Chan, Yiong Huak Cheung, Peter PM Lahiri, Manjari J Autoimmun Article BACKGROUND: Studies of flares of autoimmune inflammatory rheumatic diseases (AIIRD) after COVID-19 mRNA vaccination are limited by small sample size, short follow up or at risk of selection bias. METHODS: A national retrospective cohort study of consecutive AIIRD patients ≥12 years old, across 8 hospitals who received at least one dose of a COVID-19 mRNA vaccine. Patients were included from the date of 1st vaccine dose and censored at the time of flare or on the date of the clinic visit at least 3 months from cohort entry, whichever came first. Predictors of flare were determined by Cox proportional hazards analysis. FINDINGS: 4627 patients (73% Chinese, 71% female) of median (IQR) age 61 (48, 70) years were included; 42% Rheumatoid arthritis, 14% Systemic lupus erythematosus and 11% Psoriatic arthritis. 47% were in remission, 41% low disease activity, 10% moderate disease activity and 1% in high disease activity. 18% patients flared, of which 11.7% were within the 3-month period of interest. 11.8% patients improved. Median (IQR) time-to-flare was 60 (30, 114) days. 25% flares were self-limiting, 61% mild-moderate and 14% severe. Older patients (53–65 years and >66 years) had a lower risk of flare [HR 0.6 (95% CI 0.5–0.8) and 0.7 (0.6–0.8) respectively]. Patients with inflammatory arthritis and with active disease had a higher risk of flare [HR 1.5 (1.2–2.0) and 1.4 (1.2–1.6), respectively]. Treatment with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), immunosuppression and prednisolone was also associated with an increased risk of flare [HR 1.5 (1.1–2), 1.2 (1.1–1.4) and 1.5 (1.2–1.8) for prednisolone ≤7.5 mg respectively]. INTERPRETATION: There was a moderately high rate of AIIRD flares after mRNA vaccination but also improvement in several patients. Severe flares and hospitalisation were rare. Thus, vaccination remains safe and highly recommended. The Authors. Published by Elsevier Ltd. 2023-01 2022-11-29 /pmc/articles/PMC9705203/ /pubmed/36473406 http://dx.doi.org/10.1016/j.jaut.2022.102959 Text en © 2022 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Ma, Margaret Santosa, Amelia Fong, Warren Chew, Li-Ching Low, Andrea HL Law, Annie Poh, Yih Jia Yeo, Siaw Ing Leung, Ying Ying Ng, Victoria WW Koh, Joshua ZE Tay, Sen Hee Mak, Anselm Teng, Gim Gee Xu, Chuanhui Tang, Johnston GX Kong, Kok Ooi Angkodjojo, Stanley Goh, Wei-Rui Chuah, Tyng Yu Roslan, Nur Emillia Arkachaisri, Thaschawee Teh, Kai Liang Sriranganathan, Melonie Tan, Teck Choon Phang, Kee Fong Yap, Qai Ven Chan, Yiong Huak Cheung, Peter PM Lahiri, Manjari Post-mRNA vaccine flares in autoimmune inflammatory rheumatic diseases: Results from the COronavirus National Vaccine registry for ImmuNe diseases SINGapore (CONVIN-SING) |
title | Post-mRNA vaccine flares in autoimmune inflammatory rheumatic diseases: Results from the COronavirus National Vaccine registry for ImmuNe diseases SINGapore (CONVIN-SING) |
title_full | Post-mRNA vaccine flares in autoimmune inflammatory rheumatic diseases: Results from the COronavirus National Vaccine registry for ImmuNe diseases SINGapore (CONVIN-SING) |
title_fullStr | Post-mRNA vaccine flares in autoimmune inflammatory rheumatic diseases: Results from the COronavirus National Vaccine registry for ImmuNe diseases SINGapore (CONVIN-SING) |
title_full_unstemmed | Post-mRNA vaccine flares in autoimmune inflammatory rheumatic diseases: Results from the COronavirus National Vaccine registry for ImmuNe diseases SINGapore (CONVIN-SING) |
title_short | Post-mRNA vaccine flares in autoimmune inflammatory rheumatic diseases: Results from the COronavirus National Vaccine registry for ImmuNe diseases SINGapore (CONVIN-SING) |
title_sort | post-mrna vaccine flares in autoimmune inflammatory rheumatic diseases: results from the coronavirus national vaccine registry for immune diseases singapore (convin-sing) |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705203/ https://www.ncbi.nlm.nih.gov/pubmed/36473406 http://dx.doi.org/10.1016/j.jaut.2022.102959 |
work_keys_str_mv | AT mamargaret postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing AT santosaamelia postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing AT fongwarren postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing AT chewliching postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing AT lowandreahl postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing AT lawannie postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing AT pohyihjia postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing AT yeosiawing postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing AT leungyingying postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing AT ngvictoriaww postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing AT kohjoshuaze postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing AT taysenhee postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing AT makanselm postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing AT tenggimgee postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing AT xuchuanhui postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing AT tangjohnstongx postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing AT kongkokooi postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing AT angkodjojostanley postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing AT gohweirui postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing AT chuahtyngyu postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing AT roslannuremillia postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing AT arkachaisrithaschawee postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing AT tehkailiang postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing AT sriranganathanmelonie postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing AT tanteckchoon postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing AT phangkeefong postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing AT yapqaiven postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing AT chanyionghuak postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing AT cheungpeterpm postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing AT lahirimanjari postmrnavaccineflaresinautoimmuneinflammatoryrheumaticdiseasesresultsfromthecoronavirusnationalvaccineregistryforimmunediseasessingaporeconvinsing |